Lincoln Capital LLC decreased its position in Johnson & Johnson (NYSE:JNJ) by 0.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 30,135 shares of the company’s stock after selling 250 shares during the quarter. Johnson & Johnson comprises 1.8% of Lincoln Capital LLC’s investment portfolio, making the stock its 19th largest holding. Lincoln Capital LLC’s holdings in Johnson & Johnson were worth $4,396,000 at the end of the most recent reporting period.
Other large investors have also recently added to or reduced their stakes in the company. Krueger & Catalano Capital Partners LLC lifted its stake in Johnson & Johnson by 6.9% in the fourth quarter. Krueger & Catalano Capital Partners LLC now owns 16,620 shares of the company’s stock valued at $2,424,000 after acquiring an additional 1,072 shares during the last quarter. Vision Capital Management Inc. grew its position in Johnson & Johnson by 7.2% in the fourth quarter. Vision Capital Management Inc. now owns 24,995 shares of the company’s stock worth $3,646,000 after acquiring an additional 1,677 shares in the last quarter. Aurora Investment Managers LLC. acquired a new position in shares of Johnson & Johnson during the 4th quarter worth $2,009,000. Kiley Juergens Wealth Management LLC increased its stake in shares of Johnson & Johnson by 1.3% during the 4th quarter. Kiley Juergens Wealth Management LLC now owns 19,422 shares of the company’s stock worth $2,833,000 after purchasing an additional 248 shares during the last quarter. Finally, Verus Financial Partners Inc. raised its holdings in shares of Johnson & Johnson by 1.7% during the 4th quarter. Verus Financial Partners Inc. now owns 4,382 shares of the company’s stock valued at $639,000 after purchasing an additional 74 shares in the last quarter. Hedge funds and other institutional investors own 67.36% of the company’s stock.
Shares of Johnson & Johnson stock opened at $149.27 on Wednesday. The company has a current ratio of 1.26, a quick ratio of 1.00 and a debt-to-equity ratio of 0.46. The firm has a fifty day simple moving average of $144.44 and a 200-day simple moving average of $135.05. The stock has a market capitalization of $392.60 billion, a price-to-earnings ratio of 23.32, a PEG ratio of 2.40 and a beta of 0.71. Johnson & Johnson has a 1-year low of $125.00 and a 1-year high of $150.17.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 25th will be paid a $0.95 dividend. The ex-dividend date of this dividend is Monday, February 24th. This represents a $3.80 dividend on an annualized basis and a yield of 2.55%. Johnson & Johnson’s payout ratio is presently 46.45%.
JNJ has been the subject of several analyst reports. Barclays upgraded shares of Johnson & Johnson from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $140.00 to $173.00 in a report on Thursday, December 19th. Atlantic Securities raised shares of Johnson & Johnson from an “underweight” rating to a “neutral” rating in a research report on Wednesday, October 16th. Credit Suisse Group restated a “buy” rating and set a $163.00 target price on shares of Johnson & Johnson in a report on Tuesday, December 31st. Raymond James reduced their price target on Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating for the company in a research report on Monday, October 14th. Finally, Sanford C. Bernstein upgraded Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price target for the company in a research note on Friday, October 11th. Three equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Johnson & Johnson has a consensus rating of “Buy” and an average target price of $159.33.
In other news, Director Hubert Joly bought 5,000 shares of the business’s stock in a transaction on Friday, December 13th. The stock was purchased at an average price of $141.28 per share, with a total value of $706,400.00. Following the transaction, the director now directly owns 5,000 shares in the company, valued at $706,400. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Kathryn E. Wengel sold 2,017 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $141.07, for a total transaction of $284,538.19. Following the sale, the executive vice president now owns 51,736 shares of the company’s stock, valued at $7,298,397.52. The disclosure for this sale can be found here. Company insiders own 0.23% of the company’s stock.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: What does RSI mean?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.